SCHEMBL9769337

SCHEMBL9769337

Nc1cc(F)c(O)c(C(F)(F)F)c1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.43
GLA P06280 1/20 0.43
POLB P06746 1/20 0.43
GAA P10253 1/20 0.43
KIF11 P52732 3/20 0.41
THRB P10828 1/20 0.34
ALDH1A1 P00352 1/20 0.32
MAPT P10636 1/20 0.32
MPL P40238 2/20 0.31
KDM1A O60341 1/20 0.31
VRK1 Q99986 1/20 0.31
HTR3E A5X5Y0 1/20 0.31
HTR3B O95264 1/20 0.31
HTR3A P46098 1/20 0.31
HTR3D Q70Z44 1/20 0.31
HTR3C Q8WXA8 1/20 0.31
MAPK1 P28482 1/20 0.30
GPR3 P46089 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5511595 0.86 GAA (0.50) TSHRGLAPOLBGAAKIF11
SCHEMBL1137323 0.78 THRB (0.46) TSHRTHRBALDH1A1VRK1
SCHEMBL30568362 0.77 TSHR (0.46) TSHRGLAPOLBGAAKIF11
SCHEMBL28047962 0.77 ERN1 (0.43) KIF11
SCHEMBL10824723 0.77 TSHR (0.42) TSHRGLAPOLBGAAKIF11
SCHEMBL4846727 0.77 THRB (0.60) TSHRGLAPOLBGAATHRB
Hydrochloric Acid SCHEMBL2876394 0.76 THRB (0.43) TSHRTHRBALDH1A1MAPTVRK1
SCHEMBL15543679 0.74 GAA (0.43) TSHRGLAPOLBGAAKIF11
SCHEMBL20600783 0.74 KIF11 (0.37) TSHRKIF11KDM1A
SCHEMBL22133464 0.74 THRB (0.42) TSHRGAATHRBALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3638670-B1 SUBSTITUTED PYRROLOPYRIDINE-DERIVATIVES AS MAP4K1 MODULATORS FOR THE TREATMENT OF CANCER DISEASES Bayer Pharma AG (DE) 2021-07-21 EP disclosed
EP-3638670-A1 SUBSTITUTED PYRROLOPYRIDINE-DERIVATIVES AS MAP4K1 MODULATORS FOR THE TREATMENT OF CANCER DISEASES Bayer Pharma Aktiengesellschaft (DE) 2020-04-22 EP disclosed
WO-2018228923-A1 SUBSTITUTED PYRROLOPYRIDINE-DERIVATIVES AS MAP4K1 MODULATORS FOR THE TREATMENT OF CANCER DISEASES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-12-20 WO disclosed
US-5068436-A Hydrogenation of halonitrobenzenes without dehalogenation E. I. DU PONT DE NEMOURS AND COMPANY (US) 1991-11-26 US disclosed